Khapzory is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Khapzory is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameKhapzory
Authorized genericlevoleucovorin
Regular genericlevoleucovorin
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Khapzory?
The original
–
–

Brand nameThe maker’s card

Acrotech Access Support co-pay assistance

Savings card from Acrotech Biopharma

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $25 an infusion

The card takes up to $10,000 a year off your co-pay.

Sign up on acrotechpatientaccess.com 

In the maker’s words

“Subsequent Dates of Service: Patient will be responsible for the first $25 of the co-insurance/cost share for the Acrotech product. STAR will cover the remaining cost share for the Acrotech product at 100%.”

From the maker’s offer on acrotechpatientaccess.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Khapzory itself, from the same company, sold without the brand name, and usually for less. For now Khapzory is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

KHAPZORY is a folate analog indicated for:

  • Rescue after high-dose methotrexate therapy in adults and pediatric patients with osteosarcoma.
  • Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients.
  • Treatment of adults with metastatic colorectal cancer in combination with fluorouracil.

Limitations of Use

KHAPZORY is not indicated for pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12 because of the risk of progression of neurologic manifestations despite hematologic remission.

Source: the FDA label for Khapzory (Acrotech Biopharma Inc), March 17, 2026. Full label on DailyMed 

Good to know